CoreFirst Bank & Trust’s Jazz Pharmaceuticals JAZZ Stock Holding History

CoreFirst Bank & Trust’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$42.5K	Hold	225	–	–	0.02%	212
2025 Q4	$38.3K	Hold	225	–	–	0.02%	223
2025 Q3	$29.7K	Hold	225	–	–	0.02%	237
2025 Q2	$23.9K	Buy	+225	New	+$24.4K	0.01%	250
2025 Q1	–	Sell	-225	Closed	-$27.7K	–	228
2024 Q4	$27.7K	Hold	225	–	–	0.02%	250
2024 Q3	$25.1K	Buy	+225	New	+$24.7K	0.01%	248
2024 Q2	–	Sell	-225	Closed	-$27.1K	–	240
2024 Q1	$27.1K	Hold	225	–	–	0.02%	255
2023 Q4	$27.7K	Hold	225	–	–	0.02%	253
2023 Q3	$29.1K	Hold	225	–	–	0.02%	271
2023 Q2	$27.9K	Hold	225	–	–	0.02%	258
2023 Q1	$32.9K	Hold	225	–	–	0.02%	250
2022 Q4	$35.8K	Hold	225	–	–	0.03%	265
2022 Q3	$30K	Hold	225	–	–	0.03%	256
2022 Q2	$35K	Hold	225	–	–	0.03%	241
2022 Q1	$35K	Hold	225	–	–	0.02%	277
2021 Q4	$29K	Hold	225	–	–	0.02%	306
2021 Q3	$29K	Hold	225	–	–	0.02%	312
2021 Q2	$40K	Hold	225	–	–	0.03%	284
2021 Q1	$37K	Hold	225	–	–	0.03%	281
2020 Q4	$37K	Buy	+225	New	+$33.5K	0.03%	259

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CoreFirst Bank & Trust's JAZZ Position: Q1 2026 in Review

CoreFirst Bank & Trust held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2026 at 225 shares worth $42.5K. The position accounts for 0.02% of the portfolio, ranked #212.

CoreFirst Bank & Trust first reported a position in JAZZ in Q4 2020 and has held it in 20 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

CoreFirst Bank & Trust held 225 shares of Jazz Pharmaceuticals worth $42.5K as of Q1 2026.
CoreFirst Bank & Trust left its Jazz Pharmaceuticals share count unchanged in Q1 2026.
Jazz Pharmaceuticals made up 0.02% of CoreFirst Bank & Trust's portfolio in Q1 2026, its #212 holding.
CoreFirst Bank & Trust first reported a position in Jazz Pharmaceuticals in Q4 2020 and has held it in 20 quarters since.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on CoreFirst Bank & Trust's 13F filing for Q1 2026, filed 3 Jun 2026.